<DOC>
	<DOCNO>NCT02385526</DOCNO>
	<brief_summary>Post-market , on-label , double-blind , randomize , prospective , interventional , tolerability clinical outcome study determine number patient achieve final assign VNS Therapy dose setting patient drug-resistant epilepsy treat adjunctive VNS Therapy use new titration protocol .</brief_summary>
	<brief_title>Vagus Nerve Stimulation Titration Protocol Improve Tolerance Accelerate Adaptation</brief_title>
	<detailed_description>Post-market , on-label , double-blind , randomize , prospective , interventional , tolerability clinical outcome study design determine VNS Therapy titration paradigm allow patient achieve therapeutic dose within specified time frame . Additionally , study collect data acute tolerability clinical outcome patient drug-resistant epilepsy treat adjunctive VNS Therapy employ three different titration paradigm .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<criteria>1 . Patients must agree treated VNS Therapy . The decision treat VNS Therapy must make independent prior participation study . 2 . Patients must 12 year older partial onset seizure must follow indication use statement VNS Therapy . 3 . Patient and/or caregiver must able willing give accurate side effect report , global impression data complete study instrument minimal assistance throughout study . 4 . Patient legal guardian understands study procedure voluntarily sign inform consent Health Insurance Portability Accountability Act ( HIPAA ) authorization accordance institutional policy . In event patient age 18 , patient also require sign assent affirm agreement participate research accord local IRB requirement . 5 . Patient must take least 1 antiepileptic drug treatment 1 . Patient currently use , expect use study , shortwave diathermy , microwave diathermy , therapeutic ultrasound diathermy . 2 . Patient expect require MRI use body coil transmission RF clinical study . 3 . Patient progressive neurological condition ( e.g . brain tumor etc. ) . 4 . In investigator 's opinion , patient legal guardian unable comply frequency clinic visit study . 5 . Patient currently use investigational device pharmacologic medication approve FDA . 6 . Patient previously implant VNS Therapy . 7 . In investigator 's opinion , patient consider suicide risk otherwise good candidate study . 8 . Patient/Caregiver unable complete require study followup visit assessment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Vagus Nerve Stimulation</keyword>
	<keyword>ASCEND</keyword>
	<keyword>VNS Titration Improve Tolerance Accelerate Adaptation</keyword>
</DOC>